

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4842634

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
COREY M. DAMBACHER	02/22/2018
DEVON CAYER	02/19/2018
RICHARD LECOULTRE	01/23/2018
JOSEPH ROKICKI	01/16/2018
KERRY WILSON	02/13/2018
EUGENE TU	01/29/2018
KANDASWAMY VIJAYAN	01/26/2018
RECEIVING PARTY DATA	
Name:	OMNIOME, INC.
Street Address:	10575 ROSELLE STREET
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15851383
CORRESPONDENCE DATA	
Fax Number:	(858)350-6111
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	858-350-6100
Email:	wgorman@kilpatricktownsend.com, ipefiling@kilpatricktownsend.com
Correspondent Name:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 1:	1100 PEACHTREE STREET
Address Line 2:	SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	097128-1068657-020US1
NAME OF SUBMITTER:	WILLIAM H. GORMAN
SIGNATURE:	/William H. Gorman/
DATE SIGNED:	02/27/2018

PATENT

Total Attachments: 16

source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page1.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page2.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page3.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page4.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page5.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page6.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page7.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page8.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page9.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page10.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page11.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page12.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page13.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page14.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page15.tif
source=OMN-020US1_2018-02-27_Assignment_097128-1069657#page16.tif

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE NUCLEOTIDES,”

filed with the U.S. Patent and Trademark Office on December 21, 2017

and assigned serial no. 15/851,383

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Omniome, Inc., a corporation having a principal place of business at 10575 Roselle Street, San Diego, California 92121 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and


ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 2 of 4

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our signatures.

Signature: 
Corey M. Dambacher

Date: 2/22/18


Signature: _____
Devon Cayer

Date: _____

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 3 of 4

Signature: 
Richard LeCoulre

Date: 1/23/18

Signature: 
Joseph Rokicki

Date: 1/16/2018

Signature: _____
Kerry Wilson

Date: _____

Signature: _____
Eugene Tu

Date: _____

Signature: _____
Kandaswamy Vijayan

Date: _____

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 4 of 4

Accepted and Agreed to By:

OMNIOME, INC.

Date: 2/27/18

By: David Mulderkey
Name: DAVID MULDERKEY

Title: CEO

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE NUCLEOTIDES,”

filed with the U.S. Patent and Trademark Office on December 21, 2017

and assigned serial no. 15/851,383

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Omniome, Inc., a corporation having a principal place of business at 10575 Roselle Street, San Diego, California 92121 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 2 of 4

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our signatures.

Signature: _____

Corey M. Dambacher

Date: _____

Signature: Devon Cayer

Devon Cayer

Date: 02/19/18

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 3 of 4

Signature: _____

Richard LeCoultre

Date: _____

Signature: _____

Joseph Rokicki

Date: _____

Signature:  _____

Kerry Wilson

Date: 2/13/2018

Signature: _____

Eugene Tu

Date: _____

Signature: _____

Kandaswamy Vijayan

Date: _____

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 4 of 4

Accepted and Agreed to By:

OMNIOME, INC.

Date: 2/27/18

By: David Mulderkey
Name: DAVID MULDERKEY

Title: CEO

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE NUCLEOTIDES,”

filed with the U.S. Patent and Trademark Office on December 21, 2017

and assigned serial no. 15/851,383

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Omniome, Inc., a corporation having a principal place of business at 10575 Roselle Street, San Diego, California 92121 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 2 of 4

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our signatures.

Signature: _____

Corey M. Dambacher

Date: _____

Signature: Devon Cayer

Devon Cayer

Date: 02/19/18

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 3 of 4

Signature: _____

Richard LeCoultre

Date: _____

Signature: _____

Joseph Rokicki

Date: _____

Signature: _____

Kerry Wilson

Date: _____

Signature:  _____

Eugene Tu

Date: 01-29-2018

Signature: _____

Kandaswamy Vijayan

Date: _____

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 4 of 4

Accepted and Agreed to By:

OMNIOME, INC.

Date: 2/27/18

By: David Mulderkey
Name: DAVID MULDERKEY

Title: CEO

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE NUCLEOTIDES,”

filed with the U.S. Patent and Trademark Office on December 21, 2017

and assigned serial no. 15/851,383

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Omniome, Inc., a corporation having a principal place of business at 10575 Roselle Street, San Diego, California 92121 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 2 of 4

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our signatures.

Signature: _____

Corey M. Dambacher

Date: _____

Signature: Devon Cayer

Devon Cayer

Date: 02/19/18

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 3 of 4

Signature: _____

Richard LeCoultre

Date: _____

Signature: _____

Joseph Rokicki

Date: _____

Signature: _____

Kerry Wilson

Date: _____

Signature: _____

Eugene Tu

Date: _____

Signature:  _____

Kandaswamy Vijayan

Date: 1/26/2018

ASSIGNMENT
METHOD AND SYSTEM EMPLOYING DISTINGUISHABLE POLYMERASES FOR
DETECTING TERNARY COMPLEXES AND IDENTIFYING COGNATE
NUCLEOTIDES

Attorney Docket No. 097128-1069657-020US1

Page 4 of 4

Accepted and Agreed to By:

OMNIOME, INC.

Date: 2/27/18

By: David Mulvaney
Name: DAVID MULVANNEY

Title: CEO